Valuation : Tectonic Therapeutic, Inc.

Market Cap 585M 504M 473M 432M 811M 55.69B 817M 5.61B 2.18B 28.24B 2.2B 2.15B 93.51B P/E 2026 *
-5.88x
P/E 2027 * -5.53x
Enterprise Value 111M 95.66M 89.83M 82M 154M 10.57B 155M 1.06B 414M 5.36B 417M 408M 17.75B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
62.15%
Yield 2026 *
-
Yield 2027 * -
1 day-15.95%
1 week-17.91%
Current month+6.81%
1 month+6.81%
3 months+3.63%
6 months+22.73%
Current year+43.53%
1 week 29.78
Extreme 29.78
38.85
1 month 27.3
Extreme 27.305
38.85
Current year 16.77
Extreme 16.77
39.53
1 year 14.38
Extreme 14.385
39.53
3 years 13.7
Extreme 13.7
61.07
5 years 13.7
Extreme 13.7
61.07
10 years 13.7
Extreme 13.7
61.07
Date Insider Type Main position Quantity % Market Cap. Importance
25/08/26 Exercice

Chief Technology Officer

129 0.0007%
12/08/26 Exercice

Chief Technology Officer

129 0.0007%
30/06/26 Exercice

Chief Technology Officer

516 0.0027%
Change 5-day change 1-year change 3-year change Capi.($)
-15.95%-17.91%+79.82% - 585M
-1.66%-4.96%+49.84%+88.43% 68.13B
+0.64%+1.85%+45.30%+89.37% 63.6B
+1.31%+1.81%+37.52%+12.07% 25.57B
+2.77%-1.74%-16.16%+456.51% 26.6B
-0.46%-9.94%+0.98%-15.98% 25.52B
-9.71%-0.36%+245.87%+377.68% 18.23B
-0.49%-0.24%+28.44%-20.19% 19.69B
-1.49%-6.35%+0.78%+540.26% 15.16B
+0.35%+0.16%+46.96%+144.04% 13.54B
Average -2.49%-4.23%+51.93%+185.80% 27.66B
Weighted average by Cap. -0.72%-2.37%+45.43%+146.29%

Financials

2026 *2027 *
Net sales - -
Net income -101M -87.14M -81.82M -74.69M -140M -9.63B -141M -970M -377M -4.88B -380M -372M -16.17B -132M -114M -107M -97.6M -183M -12.58B -185M -1.27B -493M -6.38B -497M -486M -21.13B
Net Debt -474M -408M -383M -350M -657M -45.12B -662M -4.54B -1.77B -22.88B -1.78B -1.74B -75.76B -343M -295M -277M -253M -476M -32.64B -479M -3.29B -1.28B -16.55B -1.29B -1.26B -54.8B
Logo Tectonic Therapeutic, Inc.
Tectonic Therapeutic, Inc. is a clinical-stage biotechnology company. The Company is focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs). Its technology platform called GEODe (GPCRs Engineered for Optimal Discovery), is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery and harness the human body to modify the course of disease. Its product candidates are TX45, a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone relaxin. Its second development candidate, TX2100, is a VHH-Fc fusion antagonist antibody that binds to the APJ receptor (APLNR), also known as the apelin receptor. Its APJ is a differentiated approach for the treatment of hereditary hemorrhagic telangiectasia (HHT) and is a selective anti-angiogenic target that is primarily expressed in endothelial cells.
Employees
60
Date Price Change Volume
31/08/26 $29.94 -15.95% 719,569
28/08/26 $35.62 -2.94% 157,791
27/08/26 $36.70 +2.03% 278,134
26/08/26 $35.97 -4.61% 145,166
25/08/26 $37.71 +3.40% 144,458
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
29.94USD
Average target price
77.56USD
Spread / Average Target
+159.04%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TECX Stock